Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to SLC39A4" (ENSG00000272115) denotes an uncharacterized non-coding RNA transcribed from the region opposite to the SLC39A4 gene, which encodes the zinc transporter ZIP4[1][3][7]. Antisense transcripts may regulate the expression of their sense gene partners via RNA interference or epigenetic mechanisms, but for ENSG00000272115, there is currently no known molecular function, biological role, disease association, or experimental evidence supporting its relevance as a drug target. It is not recognized as a receptor, transporter, enzyme, or other classical druggable entity. No aliases, clinical biomarkers, or reported interactions exist for this RNA. If a therapeutic or diagnostic interest in the antisense regulation of SLC39A4 emerges in the future, this could change, but at present, it should not be considered a canonical target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to SLC39A4 (ENSG00000272115).